Show simple item record Bernardini, MQ Baba, T Lee, PS Barnett, JC Sfakianos, GP Secord, AA Murphy, SK Iversen, E Marks, JR Berchuck, A
dc.coverage.spatial England 2011-06-21T17:29:35Z 2010-05-26
dc.identifier 1471-2407-10-237
dc.identifier.citation BMC Cancer, 2010, 10 pp. 237 - ?
dc.description.abstract BACKGROUND: Mutations in the TP53 gene are extremely common and occur very early in the progression of serous ovarian cancers. Gene expression patterns that relate to mutational status may provide insight into the etiology and biology of the disease. METHODS: The TP53 coding region was sequenced in 89 frozen serous ovarian cancers, 40 early stage (I/II) and 49 advanced stage (III/IV). Affymetrix U133A expression data was used to define gene expression patterns by mutation, type of mutation, and cancer stage. RESULTS: Missense or chain terminating (null) mutations in TP53 were found in 59/89 (66%) ovarian cancers. Early stage cancers had a significantly higher rate of null mutations than late stage disease (38% vs. 8%, p < 0.03). In advanced stage cases, mutations were more prevalent in short term survivors than long term survivors (81% vs. 30%, p = 0.0004). Gene expression patterns had a robust ability to predict TP53 status within training data. By using early versus late stage disease for out of sample predictions, the signature derived from early stage cancers could accurately (86%) predict mutation status of late stage cancers. CONCLUSIONS: This represents the first attempt to define a genomic signature of TP53 mutation in ovarian cancer. Patterns of gene expression characteristic of TP53 mutation could be discerned and included several genes that are known p53 targets or have been described in the context of expression signatures of TP53 mutation in breast cancer.
dc.format.extent 237 - ?
dc.language eng
dc.language.iso en_US en_US
dc.relation.ispartof BMC Cancer
dc.relation.isversionof 10.1186/1471-2407-10-237
dc.subject Algorithms
dc.subject Cluster Analysis
dc.subject DNA Mutational Analysis
dc.subject Female
dc.subject Gene Expression Profiling
dc.subject Gene Expression Regulation, Neoplastic
dc.subject Humans
dc.subject Mutation
dc.subject Neoplasm Staging
dc.subject Oligonucleotide Array Sequence Analysis
dc.subject Ovarian Neoplasms
dc.subject Prognosis
dc.subject Survival Analysis
dc.subject Survivors
dc.subject Time Factors
dc.subject Tumor Suppressor Protein p53
dc.title Expression signatures of TP53 mutations in serous ovarian cancers.
dc.title.alternative en_US
dc.type Journal Article
dc.description.version Version of Record en_US 2010-5-26 en_US
duke.description.endpage 237 en_US
duke.description.issue en_US
duke.description.startpage 237 en_US
duke.description.volume 10 en_US
dc.relation.journal Bmc Cancer en_US
pubs.organisational-group /Duke
pubs.organisational-group /Duke/School of Medicine
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Obstetrics and Gynecology
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Obstetrics and Gynecology/Obstetrics and Gynecology, Gynecologic Oncology
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Pathology
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery
pubs.organisational-group /Duke/School of Medicine/Clinical Science Departments/Surgery/Surgery, Surgical Sciences
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers
pubs.organisational-group /Duke/School of Medicine/Institutes and Centers/Duke Cancer Institute
pubs.organisational-group /Duke/Trinity College of Arts & Sciences
pubs.organisational-group /Duke/Trinity College of Arts & Sciences/Statistical Science
pubs.publication-status Published online
pubs.volume 10
dc.identifier.eissn 1471-2407

Files in this item

This item appears in the following Collection(s)

Show simple item record